Stock Screener App

Gratuito - Play StoreApp Store

Installare Installare

Dow:

Nasdaq:

S&P 500:

SMMT

$16.031.05%-0.17

Dopo l'orario di chiusura: 15.98-0.05 -0.31%

Summit Therapeutics Inc (SMMT)

Date: O: H: L: C: Vol:

Summit Therapeutics Inc Borsa (SMMT) Ultime notizie

AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales Growth - Zacks Investment Research

Summit Expands Ashburn Data Center Capacity by 60% as Hyperscale Demand Squeezes Enterprise Colocation Market - GlobeNewswire Inc.

Breakfast News: Science Strikes Back at Cancer - The Motley Fool

Summit Expands Ivonescimab Development Into Biliary Tract Cancer - Zacks Investment Research

Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential? - Zacks Investment Research

For distant-stage biliary cancer, estimated five-year survival is under 5%. Summit plans a drug-combination trial. - Stock Titan

Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma - Investing News Network

A share-increase proposal at Summit Therapeutics (SMMT) would help enable conversion of $2B in preferred stock. - Stock Titan

Accounting chief gets a stock grant at Summit Therapeutics (SMMT), vesting in 2029 if still employed. - Stock Titan

Summit Therapeutics Inc Stock (SMMT) Moved Down by 8.61% on Oct 13: Key Drivers Unveiled - TradingKey

A $2B financing leads Summit Therapeutics (SMMT) to ask investors for more authorized shares. - Stock Titan

AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics - citybiz

AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics - Investing News Network

SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos - Zacks Investment Research

Summit Therapeutics (NasdaqGM:SMMT) Stock Forecast & Analyst Predictions - Simply Wall Street

AstraZeneca (AZN) Puts $2 Billion Into Summit Therapeutics (SMMT) for a Cancer Tie-Up - Yahoo Finance

Summit Therapeutics Stock Climbs Wednesday: What's Happening? - Benzinga

AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets - 24/7 Wall St.

Summit Therapeutics secures major AstraZeneca equity partnership - The Globe and Mail

AstraZeneca’s $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets - Yahoo Finance

Roundup: Hengrui Pharma and Novo Enter Exclusive License Agreement for HRS-1596, AstraZeneca Enters Collaboartion with Summit Therapeutics - Pharmaceutical Executive

AstraZeneca Invests $2B in Summit for Cancer Drug Dev - Rediff MoneyWiz

Summit Therapeutics Soars Nearly 20% After AstraZeneca Bets $2 Billion on Cancer Drug Ivonescimab - Benzinga

Summit Therapeutics Shares Rise 22% After $2 Billion AstraZeneca Investment - Yahoo Finance

Summit Therapeutics Raises $2.0 Billion in Convertible Preferred Private Placement With AstraZeneca - TradingView

AstraZeneca invests $2bn in Summit Therapeutics to develop cancer drug - Business Weekly

Summit snags $2B investment from AstraZeneca, clearing financial overhang - BioSpace

AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up - Reuters

AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal - Proactive financial news

Summit Therapeutics agrees to US$2B AstraZeneca equity investment - Mugglehead Investment Magazine

AstraZeneca invests $2 billion in Summit Therapeutics By Investing.com - Investing.com

Summit Therapeutics rises after AstraZeneca commits $2B investment - TradingView

AstraZeneca announces strategic equity investment and clinical collaboration with Summit Therapeutics to advance leading ADC combination strategy in cancer - AstraZeneca

AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics - Business Wire

AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal - Yahoo Finance UK

AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal - Yahoo Finance

Summit Therapeutics (SMMT) Shows Promising Trial Results but Faces Valuation Challenges - GuruFocus

Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial (SMMT:NASDAQ) - Seeking Alpha

Summit Therapeutics (SMMT) Gains Attention as Phase III Trial Data Boosts Outlook Amid Valuation Challenges - GuruFocus

Jefferies upgrades Summit Therapeutics stock rating on trial outlook By Investing.com - Investing.com South Africa

Summit Therapeutics Shares Rise After Upgrade From Jefferies - marketscreener.com

Summit Therapeutics shares gain after Jefferies upgrades stock to Buy - Yahoo Finance

Summit Therapeutics stock surges on Jefferies upgrade to buy By Investing.com - Investing.com Canada

Jefferies upgrades Summit Therapeutics stock rating on trial outlook By Investing.com - Investing.com Canada

Jefferies upgrades Summit Therapeutics stock rating on trial outlook By Investing.com - Investing.com UK

Summit Therapeutics Inc. (SMMT) Investor Outlook: Exploring A Potential 61.45% Upside - DirectorsTalk Interviews

Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress - Yahoo Finance

Ivonescimab Demonstrates an Overall Survival Benefit in Advanced NSCLC - Summit Therapeutics - Oncodaily

Why Summit Therapeutics (SMMT) Is Up 19.5% After New Ivonescimab Phase III Survival Data - And What's Next - simplywall.st

Summit Therapeutics: The High Stakes Of Translating China Clinical Data To The U.S. (SMMT) - Seeking Alpha

Simile a SMMT

JAZZ$215.983.92%

TECH$72.660.07%

BMRN$58.511.77%

BBIO$74.955.97%

KYMR$126.633.29%

HALO$130.910.21%